Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomised, Double-blind, Phase II Trial of Adjuvant Durvalumab or Placebo for Completely Resected Esophageal Squamous Cell Carcinoma Previously Treated With Neoadjuvant Concurrent Chemoradiotherapy

NCT02520453 is registered in ClinicalTrials.gov with Samsung Medical Center as lead sponsor.

NCT NCT02520453
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02520453 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomised, Double-blind, Phase II Trial of Adjuvant Durvalumab or Placebo for Completely Resected Esophageal Squamous Cell Carcinoma Previously Treated With Neoadjuvant Concurrent Chemoradiotherapy
Lead sponsor
Samsung Medical Center
Phase
Phase 2
Overall status
Unknown status
Start date
February 29, 2016
Completion date
December 31, 2021
Enrollment
86 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

esophageal cancer